3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
5
Phase 1
5
Phase 2
4
Phase 3
3
Phase NA
1
Phase 2/3
1
Status
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
3
Gastrointestinal
2
Lymphoid
1
CNS
1
Conditions
Breast Neoplasms
1129
Triple Negative Breast Neoplasms
85
Neoplasm Metastasis
62
Neoplasms
40
Breast Neoplasms, Male
20
Prostatic Neoplasms
19
Carcinoma, Intraductal, Noninfiltrating
19
Neutropenia
18
HER2-positive Breast Cancer
17
Breast Carcinoma In Situ
17
Pain
16
Carcinoma, Ductal, Breast
16
Hot Flashes
15
Lung Neoplasms
14
Inflammatory Breast Neoplasms
14
Breast Diseases
14
Brain Neoplasms
14
Osteoporosis
13
Multiple Myeloma
13
Advanced Breast Cancer
13
Recurrence
12
Ovarian Neoplasms
12
Lymphoma, Non-Hodgkin
11
Lymphoma, Large B-Cell, Diffuse
11
Carcinoma, Ovarian Epithelial
11
Testicular Neoplasms
10
Precursor Cell Lymphoblastic Leukemia-Lymphoma
10
Lymphoma, Mantle-Cell
10
Lymphoma, Large-Cell, Immunoblastic
10
Lymphoma, Follicular
10
Interventions
Fulvestrant
2
ribociclib
1
Secretin
1
NVP-BKM120
1
Letrozole
1
CA-19-9 Antigen
1
Alpelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
Hereditary Sensory and Autonomic Neuropathies
×
Breast
×
Clear all
NCT02000089
2025-10-09
CAPS5
Johns Hopkins University
Phase 3
Recruiting
9,000 enrolled
NCT03439046
2024-08-01
BioItaLEE
Novartis
Phase 3
Completed
287 enrolled
NCT01633060
2019-01-30
BELLE-3
Novartis
Phase 3
Terminated
432 enrolled
20 charts